Evidence map›Paper›PMID 28105177›Full record

ArticleOncology letters2016

Sied Kebir, Okka Kimmich, Pitt Niehusmann, Florian C Gaertner, Markus Essler, Jennifer Landsberg, Thomas Klockgether, Matthias Simon, Ulrich Herrlinger, Martin Glas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sied KebirDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, 53127 Bonn, Germany; Stem Cell Pathologies Group, Institute of Reconstructive Neurobiology, University of Bonn Medical Center, 53127 Bonn, Germany.
Okka KimmichDepartment of Neurology, University of Bonn Medical Center, 53127 Bonn, Germany.
Pitt NiehusmannDepartment of Neuropathology, University of Bonn Medical Center, 53127 Bonn, Germany.
Florian C GaertnerDepartment of Nuclear Medicine, University of Bonn Medical Center, 53127 Bonn, Germany.
Markus EsslerDepartment of Nuclear Medicine, University of Bonn Medical Center, 53127 Bonn, Germany.
Jennifer LandsbergLaboratory of Experimental Dermatology, Department of Dermatology and Allergy, University of Bonn Medical Center, 53127 Bonn, Germany.
Thomas KlockgetherDepartment of Neurology, University of Bonn Medical Center, 53127 Bonn, Germany.
Matthias SimonDepartment of Neurosurgery, University of Bonn Medical Center, 53127 Bonn, Germany.
Ulrich HerrlingerDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, 53127 Bonn, Germany.
Martin GlasDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, 53127 Bonn, Germany; Stem Cell Pathologies Group, Institute of Reconstructive Neurobiology, University of Bonn Medical Center, 53127 Bonn, Germany; Clinical Cooperation Unit Neurooncology, MediClin Robert Janker Klinik, 53129 Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diagnosis in patients with a suspected malignant intramedullary lesion that requires biopsy for definitive diagnosis may be challenging, as spinal cord surgery carries the risk of irreversible neurological deficits. The current study presents the first case of

Indexed as

18F-fluoroethyl-L-tyrosine PETmalignant melanomaspinal cordspinal neoplasiaspinal PET

Identifiers

PMID28105177
PMCPMC5228534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.